Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.

Martínez-Calatrava MJ, González-Sánchez JL, Zabena C, Martínez-Larrad MT, Luque-Otero M, Serrano-Ríos M.

J Hypertens. 2007 Apr;25(4):773-7.

PMID:
17351368
2.

The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population.

Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C, González-Sánchez JL, Fernández-Pérez C, Serrano-Ríos M.

Diabetes Obes Metab. 2007 Jan;9(1):134-5.

PMID:
17199731
3.

The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.

Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE; HIFMECH Study Group.

J Thromb Haemost. 2003 Nov;1(11):2322-9.

4.
5.
6.

The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.

Lin S, Huiya Z, Bo L, Wei W, Yongmei G.

Endocrine. 2009 Dec;36(3):503-9. doi: 10.1007/s12020-009-9255-2. Epub 2009 Oct 24.

PMID:
19856137
7.

Gender-specific association of the plasminogen activator inhibitor-1 4G/5G polymorphism with central arterial blood pressure.

Björck HM, Eriksson P, Alehagen U, De Basso R, Ljungberg LU, Persson K, Dahlström U, Länne T.

Am J Hypertens. 2011 Jul;24(7):802-8. doi: 10.1038/ajh.2011.63. Epub 2011 Apr 14.

PMID:
21490692
8.

PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.

Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, Wilson PW, Feng D, Tofler GH, Cupples LA.

Obesity (Silver Spring). 2006 May;14(5):753-8.

10.

Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.

Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, Patrassi GM, Lombardi AM, Fabris R, Girolami A.

Thromb Haemost. 2001 Nov;86(5):1161-9.

PMID:
11816701
11.

Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women.

Kim KN, Kim KM, Kim BT, Joo NS, Cho DY, Lee DJ.

Chin Med J (Engl). 2012 Apr;125(7):1249-53.

PMID:
22613596
12.

The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.

Kinik ST, Ataç FB, Verdi H, Cetintaş S, Sahin FI, Ozbek N.

Clin Endocrinol (Oxf). 2005 May;62(5):607-10.

PMID:
15853833
13.

Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children.

Berberoğlu M, Evliyaoğlu O, Adiyaman P, Ocal G, Ulukol B, Simşek F, Siklar Z, Törel A, Ozel D, Akar N.

J Pediatr Endocrinol Metab. 2006 May;19(5):741-8.

PMID:
16789641
14.

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.

Jorgenson E, Deitcher SR, Cicek M, Liu X, Plummer S, Casey G, Witte JS.

Prostate. 2007 Feb 1;67(2):172-7.

PMID:
17044080
15.

PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.

Kinik ST, Ozbek N, Yuce M, Yazici AC, Verdi H, Ataç FB.

Thromb Haemost. 2008 Feb;99(2):352-6. doi: 10.1160/TH07-06-0395.

PMID:
18278185
16.

Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.

McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ.

Diabetologia. 1996 Dec;39(12):1512-8.

PMID:
8960834
17.

The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome.

Sookoian S, García SI, Gianotti TF, Dieuzeide G, González CD, Pirola CJ.

Am J Hypertens. 2005 Oct;18(10):1271-5.

PMID:
16202847
18.
19.

Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.

Onalan O, Balta G, Oto A, Kabakci G, Tokgozoglu L, Aytemir K, Altay C, Gurgey A, Nazli N.

J Thromb Thrombolysis. 2008 Dec;26(3):211-7. Epub 2007 Aug 25.

PMID:
17721742
20.

The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain.

González Sánchez JL, Proenza AM, Martínez Larrad MT, Ramis JM, Fernández Pérez C, Palou A, Serrano Ríos M.

Clin Endocrinol (Oxf). 2003 Oct;59(4):476-81.

PMID:
14510910

Supplemental Content

Support Center